Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Net Margin (2023 - 2025)

Immunome's Net Margin history spans 3 years, with the latest figure at 1157.61% for Q2 2025.

  • For Q2 2025, Net Margin rose 53482.0% year-over-year to 1157.61%; the TTM value through Dec 2025 reached 3228.83%, up 15354.0%, while the annual FY2025 figure was 3228.83%, 15354.0% up from the prior year.
  • Net Margin reached 1157.61% in Q2 2025 per IMNM's latest filing, up from 1525.5% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 121.88% in Q3 2023 to a low of 12857.05% in Q1 2024.
  • Average Net Margin over 3 years is 2486.66%, with a median of 1608.96% recorded in 2025.
  • Peak YoY movement for Net Margin: crashed -1266792bps in 2024, then soared 1133155bps in 2025.
  • A 3-year view of Net Margin shows it stood at 2421.17% in 2023, then dropped by -25bps to 3030.31% in 2024, then surged by 62bps to 1157.61% in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Net Margin are 1157.61% (Q2 2025), 1525.5% (Q1 2025), and 3030.31% (Q4 2024).